Circ_0048856 competes with ABCC1 for miR-193a-5p/miR-98-5p binding sites to promote the cisplatin resistance and tumorigenesis in lung cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer. Lancet. 2021;398(10299):535–554.
   PubMed Web of Science ®Google Scholar
• Gridelli C, Rossi A, Carbone DP, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1:15009.
   PubMed Web of Science ®Google Scholar
• Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management. Am Fam Physician. 2007;75(1):56–63.
   PubMed Web of Science ®Google Scholar
• Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. Chest. 2013;143(5 Suppl):e314S–e340S.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Michels J, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014;5:e1257.
   PubMed Web of Science ®Google Scholar
• Geng Y, Jiang J, Wu C. Function and clinical significance of circRNAs in solid tumors. J Hematol Oncol. 2018;11(1):98.
   PubMed Web of Science ®Google Scholar
• Xing L, Yang R, Wang X, et al. The circRNA circIFI30 promotes progression of triple-negative breast cancer and correlates with prognosis. Aging (Albany NY)). 2020;12(11):10983–11003.
   PubMedGoogle Scholar
• Chen RX, Liu HL, Yang LL, et al. Circular RNA circRNA_0000285 promotes cervical cancer development by regulating FUS. Eur Rev Med Pharmacol Sci. 2019;23(20):8771–8778.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhou Y, Liang G, et al. Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p. Cell Death Dis. 2019;10(2):55.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhao X, Wang Y, et al. circRNA-002178 act as a ceRNA to promote PDL1/PD1 expression in lung adenocarcinoma. Cell Death Dis. 2020;11(1):32.
   PubMed Web of Science ®Google Scholar
• Liu Z, Yu Y, Huang Z, et al. CircRNA-5692 inhibits the progression of hepatocellular carcinoma by sponging miR-328-5p to enhance DAB2IP expression. Cell Death Dis. 2019;10(12):900.
   PubMed Web of Science ®Google Scholar
• Greene J, Baird AM, Casey O, et al. Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep. 2019;9(1):10739.
   PubMed Web of Science ®Google Scholar
• Hua X, Sun Y, Chen J, et al. Circular RNAs in drug resistant tumors. Biomed Pharmacother. 2019;118:109233.
   PubMed Web of Science ®Google Scholar
• Xu J, Ji L, Liang Y, et al. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct Target Ther. 2020;5(1):298.
   PubMed Web of Science ®Google Scholar
• Ding C, Yi X, Wu X, et al. Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma. Cancer Lett. 2020;479:1–12.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zheng R, Chen J, et al. CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC). Cancer Cell Int. 2020;20:289.
   PubMed Web of Science ®Google Scholar
• He Y, Liu Y, Cha N, et al. Boosting influences from circ_0048856 on Non-Small cell lung cancer advancement Via. Aiming At miR-1287-5p. 2021.
   Google Scholar
• Chen T, Luo J, Gu Y, et al. Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines. Thorac Cancer. 2019;10(4):930–941.
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Zarrabi A, Orouei S, et al. Interplay between SOX9 transcription factor and microRNAs in cancer. Int J Biol Macromol. 2021;183:681–694.
   PubMed Web of Science ®Google Scholar
• Paskeh MDA, Mirzaei S, Orouei S, et al. Revealing the role of miRNA-489 as a new onco-suppressor factor in different cancers based on pre-clinical and clinical evidence. Int J Biol Macromol. 2021;191:727–737.
   PubMed Web of Science ®Google Scholar
• Mirzaei S, Zarrabi A, Asnaf SE, et al. The role of microRNA-338-3p in cancer: growth, invasion, chemoresistance, and mediators. Life Sci. 2021;268:119005.
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Zarrabi A, Hushmandi K, et al. Lung cancer cells and their sensitivity/resistance to cisplatin chemotherapy: Role of microRNAs and upstream mediators. Cell Signal. 2021;78:109871.
   PubMed Web of Science ®Google Scholar
• Hu C, Meiners S, Lukas C, et al. Role of exosomal microRNAs in lung cancer biology and clinical applications. Cell Prolif. 2020;53(6):e12828.
   PubMed Web of Science ®Google Scholar
• Liang Y, Song X, Li Y, et al. LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis. Mol Cancer. 2020;19(1):85.
   PubMed Web of Science ®Google Scholar
• O'Grady S, Finn SP, Cuffe S, et al. The role of DNA repair pathways in cisplatin resistant lung cancer. Cancer Treat Rev. 2014;40(10):1161–1170.
   PubMed Web of Science ®Google Scholar
• Tyers M, Wright GD. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat Rev Microbiol. 2019;17(3):141–155.
   PubMed Web of Science ®Google Scholar
• Teng JP, Yang ZY, Zhu YM, et al. Gemcitabine and cisplatin for treatment of lung cancer in vitro and vivo. Eur Rev Med Pharmacol Sci. 2018;22(12):3819–3825.
   PubMed Web of Science ®Google Scholar
• Hong Y, Che S, Hui B, et al. Combination therapy of lung cancer using layer-by-Layer cisplatin prodrug and curcumin Co-Encapsulated nanomedicine. Drug Des Devel Ther. 2020;14:2263–2274.
   PubMed Web of Science ®Google Scholar
• Papatsirou M, Artemaki PI, Scorilas A, et al. The role of circular RNAs in therapy resistance of patients with solid tumors. Per Med. 2020;17(6):469–490.
   PubMedGoogle Scholar
• Papatsirou M, Artemaki PI, Karousi P, et al. Circular RNAs: Emerging regulators of the major signaling pathways involved in cancer progression. Cancers (Basel. 2021;13(11):2744.
   PubMed Web of Science ®Google Scholar
• Hong W, Xue M, Jiang J, et al. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC). J Exp Clin Cancer Res. 2020;39(1):149.
   PubMed Web of Science ®Google Scholar
• Jiang F, Yu Q, Chu Y, et al. MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1. Int J Oncol. 2019;54(1):128–138.
   PubMed Web of Science ®Google Scholar
• Saw PE, Song EW. siRNA therapeutics: a clinical reality. Sci China Life Sci. 2020;63(4):485–500.
   PubMed Web of Science ®Google Scholar
• Shang Q, Yang Z, Jia R, et al. The novel roles of circRNAs in human cancer. Mol Cancer. 2019;18(1):6.
   PubMed Web of Science ®Google Scholar
• He J, Xie Q, Xu H, et al. Circular RNAs and cancer. Cancer Lett. 2017;396:138–144.
   PubMed Web of Science ®Google Scholar
• Song LN, Qiao GL, Yu J, et al. Hsa_circ_0003998 promotes epithelial to mesenchymal transition of hepatocellular carcinoma by sponging miR-143-3p and PCBP1. J Exp Clin Cancer Res. 2020;39(1):114.
   PubMed Web of Science ®Google Scholar
• Chen J, Gao S, Wang C, et al. Pathologically decreased expression of miR-193a contributes to metastasis by targeting WT1-E-cadherin axis in non-small cell lung cancers. J Exp Clin Cancer Res. 2016;35(1):173.
   PubMedGoogle Scholar
• Zhang Z, Yan Y, Zhang B, et al. Long non-coding RNA SNHG17 promotes lung adenocarcinoma progression by targeting the microRNA-193a-5p/NETO2 axis. Oncol Lett. 2021;22(6):818.
   PubMed Web of Science ®Google Scholar
• Ke SB, Qiu H, Chen JM, et al. ALG3 contributes to the malignancy of non-small cell lung cancer and is negatively regulated by MiR-98-5p. Pathol Res Pract. 2020;216(3):152761.
   PubMed Web of Science ®Google Scholar
• Kunická T, Souček P. Importance of ABCC1 for cancer therapy and prognosis. Drug Metab Rev. 2014;46(3):325–342.
   PubMed Web of Science ®Google Scholar
• Munoz M, Henderson M, Haber M, et al. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life. 2007;59(12):752–757.
   PubMed Web of Science ®Google Scholar